Transition Metal-Based Therapies for Inflammatory Diseases

Inflammatory disease (ID) is a general term that covers all diseases in which chronic inflammation performs as the major manifestation of pathogenesis. Traditional therapies based on the anti-inflammatory and immunosuppressive drugs are palliative with the short-term remission. The emergence of nanodrugs has been reported to solve the potential causes and prevent recurrences, thus holding great potential for the treatment of IDs. Among various nanomaterial systems, transition metal-based smart nanosystems (TMSNs) with unique electronic structures possess therapeutic advantages owing to their large surface area to volume ratio, high photothermal conversion efficiency, X-ray absorption capacity, and multiple catalytic enzyme activities. In this review, the rationale, design principle, and therapeutic mechanisms of TMSNs for treatments of various IDs are summarized. Specifically, TMSNs can not only be designed to scavenge danger signals, such as reactive oxygen and nitrogen species and cell-free DNA, but also can be engineered to block the mechanism of initiating inflammatory responses. In addition, TMSNs can be further applied as nanocarriers to deliver anti-inflammatory drugs. Finally, the opportunities and challenges of TMSNs are discussed, and the future directions of TMSN-based ID treatment for clinical applications are emphasized.

Recent advances in ionic liquids and nanotechnology for drug delivery

In drug discovery and drug development, it is estimated that around 40% of commercialized and 90% of under-study drugs have inadequate pharmaceutical properties, severely impairing its therapeutic efficacy. Thus, there is a strong demand to find strategies to enhance the delivery of such drugs. Ionic liquids are a novel class of liquids composed of a combination of organic salts that are of particular interest alone or in combination with drug delivery systems. This review is focused on the recent efforts using ionic liquids in drug solubility, formulation and drug delivery with specific emphasis on nanotechnology. The latest developments using hybrid delivery systems obtained upon the combination of drug delivery systems and ionic liquids will also be addressed.

Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review

Hypoxia is a salient feature observed in most solid malignancies that holds a pivotal role in angiogenesis, metastasis and resistance to conventional cancer therapeutic approaches, and thus enables cancer progression. However, the typical characteristics of hypoxic cells such as low oxygen levels and highly bio-reductive environment can offer stimuli-responsive drug release to aid in tumor-specific chemo, radio, photodyanamic and sonodynamic therapies. This approach based on targeting the poorly oxygenated tumor habitats offers the prospective to overcome the difficulties that arises due to heterogenic nature of tumor and could be possibly used in the design of diagnostic as well as therapeutic nanocarriers for targeting various types of solid cancers. Consequently, hypoxia triggered nanoparticle based drug delivery systems is a rapidly progressing research area in developing effective strategies to combat drug-resistance in solid tumors. The present review presents the recent advances in the development of hypoxia-responsive nanovehicles for drug delivery to heterogeneous tumors. The initial sections of the article provides insights into the development of hypoxia in growing cancer and its role in disease progression. The current limitations and the future prospective of hypoxia-stimulated nanomachines for cancer treatment are also discussed.

Atherosclerosis Treatment with Stimuli-Responsive Nanoagents: Recent Advances and Future Perspectives

Atherosclerosis is the root of approximately one-third of global mortalities. Nanotechnology exhibits splendid prospects to combat atherosclerosis at the molecular level by engineering smart nanoagents with versatile functionalizations. Significant advances in nanoengineering enable nanoagents to autonomously navigate in the bloodstream, escape from biological barriers, and assemble with their nanocohort at the targeted lesion. The assembly of nanoagents with endogenous and exogenous stimuli breaks down their shells, facilitates intracellular delivery, releases their cargo to kill the corrupt cells, and gives imaging reports. All these improvements pave the way toward personalized medicine for atherosclerosis. This review systematically summarizes the recent advances in stimuli-responsive nanoagents for atherosclerosis management and its progress in clinical trials.

Stereocomplexed micelle formation through enantiomeric PLA-based Y-shaped copolymer for targeted drug delivery

In this study, a novel stereocomplexed micelle system was prepared from the self-assembly of enantiomeric PLA-based Y-shaped copolymers, i.e. folic acid-adamantane/β-cyclodextrin-b-[poly(D-lactide)]₂ (FA-AD/CD-b-(PDLA)₂) and poly(2-dimethylaminoethyl methacrylate)-b-[poly(L-lactide)]₂ (PDMAEMA-b-(PLLA)₂) in aqueous solution. The newly designed Y-shaped copolymer FA-AD/CD-b-(PDLA)₂ was prepared by a combination of "click" reaction and host guest interaction between FA-AD and CD-b-(PDLA)₂. In addition, enantiomeric Y-shaped PDMAEMA-b-(PLLA)₂ copolymer was synthesized through ring-opening polymerization (ROP) of L-lactide using three-head initiator with bromo and -OH at distal ends, followed by atom transfer radical polymerization (ATRP) of DMAEMA to obtain the desired macromolecular architecture. The resultant copolymers and their intermediates were characterized by ¹H nuclear magnetic resonance (¹H NMR) and gel permeation chromatography (GPC) techniques. Due to the strong stereocomplexation interaction, FA-AD/CD-b-(PDLA)₂ and PDMAEMA-b-(PLLA)₂ mixture could self-assemble into stable mixed micelles in aqueous solution. Further, the stereocomplexed micelles exhibited excellent biocompatibility as revealed in the cytotoxicity assay. Together with the intrinsic biodegradability of PLA, it is envisioned that the stereocomplexed micelles developed in this study can be used as a promising nanocarrier for targeting drug delivery.

Hierarchically Self-Assembled Supramolecular Host-Guest Delivery System for Drug Resistant Cancer Therapy

In this report, a new star-like copolymer β-CD- g-(PNIPAAm- b-POEGA) _x, consisting of a β-CD core, grafted with temperature-responsive poly( N-isopropylacrylamide) (PNIPAAm) and biocompatible poly(oligo(ethylene glycol) acrylate) (POEGA) in a block copolymer of the arms, was used to deliver chemotherapeutics to drug resistant cancer cells and tumors. The first step of the self-assembly process involves the encapsulation of chemotherapeutics through host-guest inclusion complexation between the β-cyclodextrin cavity and the anticancer drug. Next, the chain interaction of the PNIPAAm segment at elevated temperature drives the drug-loaded β-CD- g-(PNIPAAm- b-POEGA) _x/PTX inclusion complex to hierarchically self-assemble into nanosized supramolecular assemblies at 37 °C, whereas the presence of poly(ethylene glycol) (PEG) chains in the distal end of the star-like copolymer arms impart enhanced stability to the self-assembled structure. More interestingly, this supramolecular host-guest nanocomplex promoted the enhanced cellular uptake of chemotherapeutics in MDR-1 up-regulated drug resistant cancer cells and exhibited high therapeutic efficacy for suppressing drug resistant tumor growth in an in vivo mouse model, due to the increased stability, improvement in aqueous solubility, enhanced cellular uptake, and partial membrane pump impairment by taking the advantage of PEGylation and supramolecular complex between this star-like copolymer and chemotherapeutics. This work signifies that temperature-sensitive PEGylated supramolecular nanocarriers with good biocompatibility are effective in combating MDR-1 mediated drug resistance in both in vitro and in vivo models, which is of significant importance for the advanced drug delivery platform designed to combat drug resistant cancer.

A review of recent progress in drug and protein encapsulation: Approaches, applications and challenges

Many drugs and proteins formulated for treatment of various diseases are not fully utilised due to environmentally problems such as degradation by enzymes or it being hydrophobic. To counter this problem, the drug and protein of interest are encapsulated by synthetic polymers where they are protected from the environment. This allows the molecule to reach its target safely and maximise its function. In this paper, we will discuss about the different techniques of encapsulation that includes emulsion evaporation, self-emulsifying drug delivery system and supercritical fluid. This will be followed by the drugs and proteins that are commonly encapsulated to counter life-threatening diseases such as cancer and diabetes. A novel method using foam was proposed and will be briefly discussed as it can play a huge role in future developments.